Novo Reports More Good News For Type 2 Diabetes Candidate Liraglutide
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III LEAD 1 trial shows GLP-1 analogue superior to rosiglitazone in glucose control when combined with glimepiride; LEAD 2 results also positive.
You may also be interested in...
Novo Looking To Position Liraglutide As First Once-Daily Injection Following Oral Drug Failures
Novo Nordisk reports positive top-line data from the first of five Phase III studies evaluating the GLP-1 analog.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.